Oct. 30, 2026

This article was updated Nov. 12 to reflect that this shortage is not related to the Brevera 9-gauge stereotactic breast biopsy needle recall. 

The American College of Radiology® (ACR®) offers the following information for breast imaging physicians and their practices to mitigate patient care disruptions due to a shortage of MRI breast biopsy needles.

Hologic informed users that it has voluntarily stopped shipment of ATEC® breast biopsy needles to clients following the internal identification of a manufacturing defect that requires further investigation.

Hologic does not anticipate being able to resume supply of ATEC needles before early 2027. This represents their earliest current estimate and may change as their investigation and testing progress to identify the manufacturing defect.

This supply interruption is not related to the Brevera 9-gauge stereotactic breast biopsy needle recall announced in late 2025. Hologic states that ATEC needles currently in inventory may continue to be used in accordance with their approved labeling and instructions for use.

Radiology leaders should work closely with hospital systems, referring providers and patients to coordinate safe and effective care. Due to local factors, it may not be possible for individual practices to adopt all these recommendations. 

Imaging providers should consult their legal counsel to ensure that steps outlined below meet any local, state or federal requirements and regulations. These mitigation strategies are suggestions and may not be applicable in all practices and situations.

Procedure Triage

  • Increase targeted ultrasound utilization prior to any MRI/stereo biopsy as appropriate.
  • Shift appropriate stereotactic and MRI biopsies to ultrasound-guided biopsies whenever feasible.
  • Defer low-suspicion lesions to short interval follow-up when clinically appropriate.
  • Reduce multisite stereotactic biopsies when clinically feasible.

Needle Conservation Strategies 

  • Expand supplier networks with vendor diversification.
  • Diversify and utilize all needle gauges and lengths to avoid dependence on limited “standard” inventory.
  • Utilize prior-generation devices where clinically appropriate.
  • Limit unnecessary opening/wasting of devices.
  • Obtain the appropriate standard number of samples to avoid nondiagnostic results and need for re-biopsy.

Inventory and Supply Chain Management Tips

  • Centralize inventory tracking across breast imaging sites.
  • Monitor inventory with a daily/weekly inventory dashboard available to all radiologists performing biopsy procedures.
  • Forecast utilization trends based on scheduled biopsy volumes and distribute biopsy needles appropriately across health systems/facilities.

Prioritize cases:

  • BI-RADS® 5 lesions
  • Highly suspicious masses/calcifications
  • Neoadjuvant chemotherapy cases
  • Surgical planning cases
  • High-risk discordant lesions

Consider delayed scheduling for:

  • Low-suspicion BI-RADS 4A findings 
  • If possible, use consensus reads, second read protocols, and/or panels for lesions that could be downgraded to a BIRADS 3 to allow short term follow-up instead of biopsy.
  • Nonurgent repeat biopsies if possible

Patient Communication/Clinical Care

  • Communicate delays transparently. 
  • Offer alternative biopsy locations/sites where biopsy needles may be available. 
  • Expedite surgical consultation when biopsy delay may impact care.
  • Maintain focus on minimizing delay for cancer diagnosis/treatment.

Loading component...

Loading component...